Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13315468 | 0.93 | SMN1; SMN2 (0.58) | SMN1; SMN2AKR1C3AKR1C2AKR1C1AKR1C4 | |
| SCHEMBL4492453 | 0.86 | AKR1C3 (0.43) | SMN1; SMN2AKR1C3AKR1C2AKR1C1AKR1C4 | |
| SCHEMBL31480938 | 0.86 | AKR1C3 (0.43) | SMN1; SMN2AKR1C3AKR1C2AKR1C1AKR1C4 | |
| SCHEMBL19124972 | 0.80 | KDM4E (0.53) | SMN1; SMN2HSD17B10KDM4EMAPTMEN1 | |
| SCHEMBL3164382 | 0.79 | AKR1C4 (0.43) | SMN1; SMN2AKR1C3AKR1C2AKR1C1AKR1C4 | |
| SCHEMBL13315475 | 0.79 | KDM4E (0.43) | SMN1; SMN2HSD17B10KDM4EMAPTLMNA | |
| SCHEMBL13315481 | 0.79 | PARP1 (0.46) | SMN1; SMN2HSD17B10KDM4EMAPTHTT | |
| SCHEMBL11267777 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10KDM4ELMNAHTT | |
| SCHEMBL9053612 | 0.79 | KDM4E (0.42) | SMN1; SMN2HSD17B10KDM4EMAPTLMNA | |
| Hydrochloric Acid SCHEMBL4164962 | 0.77 | MAPT (0.42) | SMN1; SMN2HSD17B10KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | claimed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | claimed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| EP-3404033-B1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2020-08-05 | — | — | EP | disclosed |
| EP-3404033-B1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2020-08-05 | — | — | EP | disclosed |
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2019-01-03 | — | — | US | disclosed |
| EP-3404033-A1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017119700-A1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 제일약품주식회사 | 2017-07-13 | — | — | WO | disclosed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| CN-1040436-C | Pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, UGGT1 | SMN1; SMN2 4298/4885AKR1C3 862/4885AKR1C2 516/4885 |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | SMN1; SMN2 4132/4885AKR1C3 348/4885AKR1C2 610/4885 |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | SLC5A2, SLC5A1, UGGT1 | SMN1; SMN2 4298/4885AKR1C3 862/4885AKR1C2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.